Pharma BD Deal Intelligence

Celltrion, Inc. / Kaigene, Inc.

2026 · Licensing/Option · $580M · Complete

Celltrion, Inc. entered an exclusive global licensing agreement with Kaigene, Inc. for KG013, a half-life-extended, fully human anti-APRIL monoclonal antibody being developed for long-acting subcutaneous administration, initially in IgA nephropathy. Celltrion receives exclusive worldwide development and commercialization rights; Kaigene retains a co-marketing option in South Korea. Kaigene is eligible to receive up to $580.5 million (approximately KRW 769 billion) in upfront and milestone payments plus royalties on net sales. The agreement is the third autoimmune-disease candidate Celltrion has licensed from Kaigene.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals